Point cloud fusion instance effect. حسب Hongliang Zou (20707270)

الموضوعات:

Youthful systemic milieu in young recipients decreased apoptosis and oxidative stress damage in allografts, and promoted proliferation. حسب Chengjun Yu (12136227)

Force analysis of the system. حسب Jianbo Jia (717814)

الموضوعات:

Comparison of detection results between YOLOv5s and P-YOLOv5s-GRNF. حسب Zhongjian Xie (4633099)

الموضوعات:

The working principle of the Welleader system. حسب Jianbo Jia (717814)

الموضوعات:

Structure of YOLOv5s-SBC. حسب Zhongjian Xie (4633099)

الموضوعات:

Local mechanism diagram of Welleader system. حسب Jianbo Jia (717814)

الموضوعات:

Structure of P-YOLOv5s-GRNF. حسب Zhongjian Xie (4633099)

الموضوعات:

Comparative experiment of different YOLOv5 versions. حسب Zhongjian Xie (4633099)

الموضوعات:

Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... حسب Marsel Ganeyev (21453399)

الموضوعات:

HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters حسب Arash GhorbanniaDelavar (22563696)

"…<h2>Summary</h2><p dir="ltr">This research introduces <b>HDECO</b> (Hybrid Decreasing Energy and Cost Optimization) — a method designed to reduce both energy consumption and execution cost in cloud datacenters through intelligent virtual machine migration. …"

CM-DWM-EC chart using 30% decrease in the mean for the E(KeV). حسب Shumaila Nisar (20114256)

"…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…"

Displacement cloud maps. حسب Maogang Tian (21485116)

الموضوعات:

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression حسب Julia Cataldo Lima (22811497)

"…This means the virus is interfering with the interferon signaling pathway, which is like the body’s alarm system for viral infections. …"

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات: